AUS
NZ
UK
CA
USA
IND
Highlights
- Dosing to start soon for TRP-8803 in clinical study
- Focus on safety and therapeutic effects for BED
- Study supported by formal regulatory approval
Tryptamine Therapeutics Ltd (ASX:TYP) is progressing with a clinical study evaluating intravenous psilocin (TRP-8803) for Binge Eating Disorder (BED). The company has partnered with Swinburne University for this world-first trial, aimed at investigating new pathways in mental health treatment. Although Tryptamine is not currently part of the ASX 200 companies, this move puts the company on the radar of biotech watchers looking at advancements in psychedelic-assisted therapies.
The study has gained formal approval from the Victorian Department of Health, allowing Swinburne University to handle controlled substances required for the trial. This regulatory clearance has enabled the next phase of preparation, which includes delivering TRP-8803 to Swinburne and initiating the participant dosing process this quarter.
Study Structure and Focus
The trial will enrol a limited group of adults diagnosed with Binge Eating Disorder. Participants will undergo dosing in a controlled medical environment, with support from psychotherapy and integration practices. This open-label format allows for the careful observation of both physical responses and psychological outcomes.
Initial steps such as patient screening and interviews are already in progress. The next milestones include enrolment finalisation and beginning of treatment, set within a structured timeline for data collection and review.
Long-Term Objectives and Observations
While the primary objective of the study is to assess the safety of repeat doses of TRP-8803, the trial will also monitor behavioural and clinical outcomes associated with the treatment. This includes tracking binge-eating frequency, psychological responses, and other health indicators. The data will help determine broader therapeutic use cases, particularly in addressing conditions that often coexist with BED.
Tryptamine Therapeutics aims to use the insights from this study to guide future development pathways and inform its strategy for clinical expansion in mental health therapies.
Frequently Asked Questions
- What is TRP-8803 being tested for?
TRP-8803 is being tested for its effects on Binge Eating Disorder in a clinical setting. - Who is conducting the study with Tryptamine Therapeutics?
The study is being conducted in collaboration with Swinburne University. - What is the goal of this trial?
The main goal is to assess the safety of TRP-8803, with additional monitoring of therapeutic outcomes related to BED.
